Opendata, web and dolomites

Fingers4Cure

Zinc finger gene therapy in the brain for treating Huntington's disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Fingers4Cure project word cloud

Explore the words cloud of the Fingers4Cure project. It provides you a very rough idea of what is the project "Fingers4Cure" about.

synthetic    earlier    synthesis    lethal    r6    zfps    garriga    data    death    huntington    viral    mutant    devastating    proof    35    parallel    therapy    market    hd    national    normal    artificially    patent    mice    intellectual    demonstrating    canut    proprietary    protect    proc    moves    finger    single    levels    dna    humans    basis    suffering    intervention    improvements    represses    clinic    vectors    al    sequences    et    zinc    diagnosis    e3136    defective    bind    109    reduce    reducing    generally    curative    45    published    htt    start    protein    repressors    maintaining    regional    accomplished    2012    licenses    engineered    e3145    coding    patients    cure    carers    neurodegenerative    symptoms    expanded    binding    inherited    15    sci    property    natl    engaging    huntingtin    toxic    age    disease    disorder    repression    function    muscle    arise    isalan    efficient    unrelated    industry    gene    grant    phases    acad    brain    usa    ipr    expression    mouse    carry    occurring    critical    proteins   

Project "Fingers4Cure" data sheet

The following table provides information about the project.

Coordinator
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE 

Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD
city: LONDON
postcode: SW7 2AZ
website: http://www.imperial.ac.uk/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 149˙995 €
 EC max contribution 149˙995 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-PoC
 Funding Scheme ERC-POC
 Starting year 2015
 Duration (year-month-day) from 2015-02-01   to  2016-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) coordinator 149˙995.00

Map

 Project objective

Huntington’s disease (HD) is a lethal inherited neurodegenerative disorder which currently has no cure. Patients develop a devastating loss of muscle control and brain function, with symptoms typically developing at 35 - 45 years of age, although they can start much earlier. Suffering is high for both patients and carers, with death generally occurring within 10 - 15 years of diagnosis. We are working on a novel, curative gene therapy approach based on reducing the levels of the HTT disease gene products, while maintaining the levels of the normal protein. It is based on the delivery of proprietary zinc finger proteins (ZFPs) to the brain. Efficient delivery is accomplished through the use of viral vectors that carry the sequences coding for our ZFPs. Such ZFPs are artificially engineered proteins that specifically bind the defective expanded HTT DNA sequences (but not the normal HTT sequences or other, unrelated sequences). Binding represses the synthesis of the toxic gene products. We have published data demonstrating efficient mutant HTT repression in mouse (Garriga-Canut, M., et al. & Isalan M. Synthetic zinc finger repressors reduce mutant Huntingtin expression in the brain of R6/2 mice. Proc Natl Acad Sci USA 109: E3136-E3145, 2012). We now need to improve the viral vectors for the long term expression of our ZFPs in the mouse brain, as the basis for a single-intervention, long-term therapy in humans (technical improvements). In parallel, we need to maintain the patent applications that protect the technology through various national and regional phases, and protect new developments that may arise (intellectual property), while engaging the necessary IPR and market studies/activities that help us find an industry partner that licenses our technology and moves it forward into the clinic (exploitation). This proof of concept grant is critical in all three aspects.

 Publications

year authors and title journal last update
List of publications.
2015 Michal Mielcarek, Mark Isalan
A shared mechanism of muscle wasting in cancer and Huntington’s disease
published pages: , ISSN: 2001-1326, DOI: 10.1186/s40169-015-0076-z
Clinical and Translational Medicine 4/1 2019-07-23
2016 Carmen Agustín-Pavón, Michal Mielcarek, Mireia Garriga-Canut, Mark Isalan
Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice
published pages: , ISSN: 1750-1326, DOI: 10.1186/s13024-016-0128-x
Molecular Neurodegeneration 11/1 2019-07-23
2015 Michal Mielcarek
Huntington\'s disease is a multi-system disorder
published pages: e1058464, ISSN: 2167-5511, DOI: 10.1080/21675511.2015.1058464
Rare Diseases 3/1 2019-07-23

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FINGERS4CURE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FINGERS4CURE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

CHIPTRANSFORM (2018)

On-chip optical communication with transformation optics

Read More  

QUAMAP (2019)

Quasiconformal Methods in Analysis and Applications

Read More  

AST (2019)

Automatic System Testing

Read More